InflaRx NV (InflaRx NV) Net Income From Continuing Operations : $-46.08 Mil (TTM As of Dec. 2023)

View and export this data going back to 2017. Start your Free Trial

What is InflaRx NV Net Income From Continuing Operations?

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. InflaRx NV's net income from continuing operations for the three months ended in Dec. 2023 was $-17.37 Mil. Its net income from continuing operations for the trailing twelve months (TTM) ended in Dec. 2023 was $-46.08 Mil.

InflaRx NV Net Income From Continuing Operations Historical Data

The historical data trend for InflaRx NV's Net Income From Continuing Operations can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

InflaRx NV Net Income From Continuing Operations Chart

InflaRx NV Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Net Income From Continuing Operations

Get a 7-Day Free Trial

-59.17

-41.34

-51.56

-31.23

-46.53

InflaRx NV Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Net Income From Continuing Operations	Get a 7-Day Free Trial															-8.50	-11.87	-8.89	-7.95	-17.37

InflaRx NV Net Income From Continuing Operations Calculation

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. It excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

Net Income From Continuing Operations for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-46.08 Mil.

InflaRx NV (InflaRx NV) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » InflaRx NV (NAS:IFRX) » Definitions » Net Income From Continuing Operations

Comparable Companies

Traded in Other Exchanges

IF0:Germany IF0:Germany

Address

Winzerlaer Strasse 2, Jena, DEU, 07745

Website

https://www.inflarx.de

InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its lead product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.